Yesterday, we reported on 2018 being a banner year for venture capital, but the New York Times says a movement of entrepreneurs is looking for other ways to raise money. . . . → Read More: Start-Ups Saying No Thanks to Venture Capital
|
|||||
|
|
A company spun-off from a university medical materials lab received start-up funds to develop a non-opioid surgical pain therapy, including a clinical trial. . . . → Read More: Spin-Off Gains Seed Funds for Non-Opioid Pain Drug 
Eli Lilly and Co. is licensing a a treatment candidate for Alzheimer’s disease from biopharmaceutical company AC Immune that aims to block accumulation of tau proteins in the brain. . . . → Read More: Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal  Comments are closed  Intellectual property, Joint ventures/collaborations  biomedical, clinical trials, equity, Europe, investment, licensing, life sciences, pharmaceuticals 
Techniques for delivering drugs in capsule form that last a week or longer in the patient are expected to receive a patent soon from U.S. authorities. . . . → Read More: Patent Set for Long-Term Drug Capsules 2 comments - (Comments are closed) Intellectual property, New products biomedical, engineering, entrepreneurs, HIV, licensing, life sciences, materials science, patent, pharmaceuticals, physical sciences, university, USPTO 
Two developers of tissue engineering technologies are building a three-dimensional bioprinter that produces high resolution, finely structured human tissue, including tiny blood vessels. . . . → Read More: Companies Partner on High-Resolution 3-D Tissue Printer Comments are closed Joint ventures/collaborations, New products biomedical, engineering, entrepreneurs, Europe, licensing, materials science, medical device, physical sciences, software, stem cells 
Results from the first 2 participants in a clinical trial show transferring healthy genes to patients with sickle cell disease reverses symptoms of the disease that continues for up to 1 year. . . . → Read More: Trial Results Show Gene Transfers Reverse Sickle Cell Disease One comment - (Comments are closed) New products biomedical, biotechnology, clinical trials, genomics, licensing, life sciences, pharmaceuticals, stem cells 
An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal Comments are closed Finance, Intellectual property biomedical, biotechnology, cancer, clinical trials, equity, Europe, investment, licensing, life sciences, pharmaceuticals, stem cells 
The company developing a treatment for a rare inherited eye disease using the genome editing technique Crispr received authorization from the Food and Drug Administration to begin clinical trials. . . . → Read More: Trials OK’d for Inherited Eye Disease Therapy with Crispr 2 comments - (Comments are closed) New products biomedical, biotechnology, clinical trials, FDA, genomics, licensing, life sciences, pharmaceuticals 
An initiative developing a contact lens that measures blood glucose levels in tear fluid is now on hold, according to Verily Life Sciences, a division of Alphabet, the parent company of Google. . . . → Read More: Update – Verily Suspends Glucose-Sensing Contact Lens Project One comment - (Comments are closed) Joint ventures/collaborations biomedical, engineering, licensing, life sciences, medical device, physical sciences 
Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal Comments are closed Intellectual property, Joint ventures/collaborations biomedical, biotechnology, equity, genomics, investment, licensing, life sciences, pharmaceuticals |
||||
|
Copyright © 2019 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||